Artificial intelligence and chimeric antigen receptor T-cell therapy

11Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Therapy with the use of chimeric antigen receptor T-cell (CAR T-cells) is one of the most modern medical technologies in hemato-oncology, using, thanks to the advances in molecular biology, natural anti-cancer immune mechanisms. Nowadays, it is an extremely effective complement to conventional treatment and hematopoietic cell transplantation. Ongoing clinical trials show the enormous potential of this treatment beyond hemato-oncology. We discuss in this paper the potential use of Artificial intelligence (AI) in this setting. AI has been at the cutting edge of science in recent years. It has spread from computer science to areas like medicine, economics, finance and business. The use of and research into AI in medicine have become prominent due to its versatility and capabilities.

Cite

CITATION STYLE

APA

Gil, L., & Grajek, M. (2022). Artificial intelligence and chimeric antigen receptor T-cell therapy. Acta Haematologica Polonica. Via Medica. https://doi.org/10.5603/AHP.A2022.0019

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free